These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 33489011)

  • 21. Impact of tetanus, diphtheria, and acellular pertussis (Tdap) vaccine use in wound management on health care costs and pertussis cases.
    Talbird SE; Graham J; Mauskopf J; Masseria C; Krishnarajah G
    J Manag Care Spec Pharm; 2015 Jan; 21(1):88-99, 99a-c. PubMed ID: 25562776
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Broder KR; Cortese MM; Iskander JK; Kretsinger K; Slade BA; Brown KH; Mijalski CM; Tiwari T; Weston EJ; Cohn AC; Srivastava PU; Moran JS; Schwartz B; Murphy TV;
    MMWR Recomm Rep; 2006 Mar; 55(RR-3):1-34. PubMed ID: 16557217
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibody persistence after vaccination of adolescents with monovalent and combined acellular pertussis vaccines containing genetically inactivated pertussis toxin: a phase 2/3 randomised, controlled, non-inferiority trial.
    Pitisuttithum P; Chokephaibulkit K; Sirivichayakul C; Sricharoenchai S; Dhitavat J; Pitisuthitham A; Phongsamart W; Boonnak K; Lapphra K; Sabmee Y; Wittawatmongkol O; Chauhan M; Wijagkanalan W; Hommalai G; Fortuna L; Chinwangso P; Poredi IK; van den Biggelaar AHJ; Pham HT; Viviani S
    Lancet Infect Dis; 2018 Nov; 18(11):1260-1268. PubMed ID: 30266329
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity and safety of the quadrivalent meningococcal vaccine MenACWY-TT co-administered with a combined diphtheria-tetanus-acellular pertussis vaccine versus their separate administration in adolescents and young adults: A phase III, randomized study.
    Rivera L; Schwarz TF; Kim KH; Kim YK; Behre U; Cha SH; Jo DS; Lee J; Lee JS; Cheuvart B; Jastorff A; Van der Wielen M
    Vaccine; 2018 Jul; 36(31):4750-4758. PubMed ID: 29960800
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomised, double-blind, non-inferiority clinical trial on the safety and immunogenicity of a tetanus, diphtheria and monocomponent acellular pertussis (TdaP) vaccine in comparison to a tetanus and diphtheria (Td) vaccine when given as booster vaccinations to healthy adults.
    Thierry-Carstensen B; Jordan K; Uhlving HH; Dalby T; Sørensen C; Jensen AM; Heilmann C
    Vaccine; 2012 Aug; 30(37):5464-71. PubMed ID: 22776216
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Boosting Teenagers With Acellular Pertussis Vaccines Containing Recombinant or Chemically Inactivated Pertussis Toxin: A Randomized Clinical Trial.
    Blanchard Rohner G; Chatzis O; Chinwangso P; Rohr M; Grillet S; Salomon C; Lemaître B; Boonrak P; Lawpoolsri S; Clutterbuck E; Poredi IK; Wijagkanalan W; Spiegel J; Pham HT; Viviani S; Siegrist CA
    Clin Infect Dis; 2019 Mar; 68(7):1213-1222. PubMed ID: 30759183
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Seroprevalence of Bordetella pertussis antibodies and anti-pertussis antibody response after a single dose of reduced-antigen combined diphtheria, tetanus, and acellular pertussis vaccine (Tdap) in pregnant Thai women.
    Sompagdee N; Anuwutnavin S; Phongsamart W; Senawong S; Umrod P; Robkhonburi A
    Vaccine; 2020 Mar; 38(12):2725-2733. PubMed ID: 32070680
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phosphate substitution in an AlOOH - TLR4 adjuvant system (SPA08) modulates the immunogenicity of Serovar E MOMP from Chlamydia trachomatis.
    Visan L; Sanchez V; Kania M; de Montfort A; de la Maza LM; Ausar SF
    Hum Vaccin Immunother; 2016 Sep; 12(9):2341-50. PubMed ID: 27104338
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Summary of the NACI Update on Immunization in Pregnancy with Tetanus Toxoid, Reduced Diphtheria Toxoid and Reduced Acellular Pertussis (Tdap) Vaccine.
    Brophy J; Baclic O; Tunis MC
    Can Commun Dis Rep; 2018 Mar; 44(3-4):91-94. PubMed ID: 31007617
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reduced-antigen, combined diphtheria-tetanus-acellular pertussis vaccine, adsorbed (Boostrix) US formulation): use as a single-dose booster immunization in adolescents aged 10-18 years.
    Frampton JE; Keam SJ
    Paediatr Drugs; 2006; 8(3):189-95; discussion 196. PubMed ID: 16774298
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity of a new enhanced tetanus-reduced dose diphtheria-acellular pertussis (Tdap) vaccine against Bordetella pertussis in a murine model.
    Kang KR; Huh DH; Kim JA; Kang JH
    BMC Immunol; 2021 Oct; 22(1):68. PubMed ID: 34641798
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Economic impact of implementing decennial tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccination in adults in the United States.
    Havers FP; Cho BH; Walker JW; Hariri S
    Vaccine; 2020 Jan; 38(2):380-387. PubMed ID: 31676198
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized Controlled Trial of the Safety and Immunogenicity of Revaccination With Tetanus-Diphtheria-Acellular Pertussis Vaccine (Tdap) in Adults 10 Years After a Previous Dose.
    Halperin SA; Donovan C; Marshall GS; Pool V; Decker MD; Johnson DR; Greenberg DP;
    J Pediatric Infect Dis Soc; 2019 May; 8(2):105-114. PubMed ID: 29438562
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized study of immune responses to two Tdap vaccines among adolescents primed with DTaP and comparison with results among adolescents primed with DTwP.
    Decker MD; Greenberg DP; Johnson DR; Pool V
    Vaccine; 2019 Aug; 37(35):5003-5008. PubMed ID: 31301919
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acellular pertussis vaccine based on outer membrane vesicles capable of conferring both long-lasting immunity and protection against different strain genotypes.
    Gaillard ME; Bottero D; Errea A; Ormazábal M; Zurita ME; Moreno G; Rumbo M; Castuma C; Bartel E; Flores D; van der Ley P; van der Ark A; F Hozbor D
    Vaccine; 2014 Feb; 32(8):931-7. PubMed ID: 24397896
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reactogenicity and immunogenicity of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant and nonpregnant women.
    Fortner KB; Swamy GK; Broder KR; Jimenez-Truque N; Zhu Y; Moro PL; Liang J; Walter EB; Heine RP; Moody MA; Yoder S; Edwards KM
    Vaccine; 2018 Oct; 36(42):6354-6360. PubMed ID: 30219367
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibody persistence and safety and immunogenicity of a second booster dose nine years after a first booster vaccination with a reduced antigen diphtheria-tetanus-acellular pertussis vaccine (Tdap) in adults.
    Brandon D; Kimmel M; Kuriyakose SO; Kostanyan L; Mesaros N
    Vaccine; 2018 Oct; 36(42):6325-6333. PubMed ID: 30197282
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tdap vaccine in pregnancy and immunogenicity of pertussis and pneumococcal vaccines in children: What is the impact of different immunization schedules?
    Febriani Y; Mansour T; Sadarangani M; Ulanova M; Amaral K; Halperin SA; De Serres G; Racine É; Brousseau N
    Vaccine; 2023 Oct; 41(45):6745-6753. PubMed ID: 37816653
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact and cost-effectiveness of a second tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine dose to prevent pertussis in the United States.
    Kamiya H; Cho BH; Messonnier ML; Clark TA; Liang JL
    Vaccine; 2016 Apr; 34(15):1832-8. PubMed ID: 26899377
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Additional recommendations for use of tetanus toxoid, reduced-content diphtheria toxoid, and acellular pertussis vaccine (Tdap).
    ;
    Pediatrics; 2011 Oct; 128(4):809-12. PubMed ID: 21949151
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.